New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2013
06:32 EDTLLYEli Lilly, Kowa says LIVALO 4 mg study met primary endpoint
Kowa Pharmaceuticals America and Eli Lilly and Company announced results of a study evaluating the efficacy of LIVALO 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholestero in HIV-infected adults with high cholesterol, or dyslipidemia. The study was designed as a superiority trial for the primary endpoint, percent reduction in LDL-C, and evaluated HIV-infected adults with dyslipidemia; with and without viral Hepatitis B or C. The study met its primary endpoint. Results showed that, after 12 weeks of therapy, pitavastatin had a significantly greater decrease in LDL-C compared with pravastatin. The results were presented yesterday at a late-breaking poster presentation at the 20th Conference on Retroviruses & Opportunistic Infections in Atlanta, GA.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
11:02 EDTLLYEli Lilly granted FDA orphan status for treatment of sickle cell disease
Subscribe for More Information
08:35 EDTLLYEli Lilly reports final results of Phase III trial for Alimta
Eli Lilly announced final results of the Phase III PROCLAIM trial, a randomized, Phase III superiority study of patients with locally-advanced, nonsquamous non-small cell lung cancer, which evaluated Lilly's Alimta in combination with cisplatin with concurrent radiation followed by maintenance Alimta in comparison with etoposide and cisplatin plus concurrent radiation, followed by consolidation chemotherapy of the oncologist's choice. Those treated on the pemetrexed arm achieved a median overall survival of 26.8 months as compared to 25 months for those treated on the etoposide arm. Median progression-free survival was 11.4 months on the pemetrexed arm versus 9.8 months on the etoposide arm and an overall response rate of 35.9% on the pemetrexed arm and 33% on the etoposide arm.
08:09 EDTLLYEli Lilly to present data from several trials of Cyramza for cancer
Subscribe for More Information
May 27, 2015
08:32 EDTLLYEli Lilly's Humalog KwikPen approved by FDA
Subscribe for More Information
May 22, 2015
10:52 EDTLLYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
07:37 EDTLLYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 14, 2015
09:22 EDTLLYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:44 EDTLLYInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
06:04 EDTLLYEli Lilly, Sanford-Burnham to investigate immunological therapies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use